Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 12, 1999, Pages 3001-3004

  Tomioka, Haruaki ^a   Sato, Katsumasa ^a   Akaki, Tatsuya ^a   Kajitani, Hiroko ^a   Kawahara, Shin ^b   Sakatani, Mitsunori ^c  

^a SHIMANE UNIVERSITY   (Japan)

^b Natl Sanat Minami Okayama Hospital   (Japan)

^c Natl Sanatorium Kinki Chuo Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 7 (7 AMINO 5 AZASPIRO[2.4]HEPT 5 YL) 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 8 METHYL 4 OXO 3 QUINOLINECARBOXYLIC ACID; CIPROFLOXACIN; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; OFLOXACIN; SITAFLOXACIN; SPARFLOXACIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG EFFECT; DRUG SCREENING; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0032762723     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.12.3001     Document Type: Article

References (29)

1. Alangaden, G. J., and S. A. Lerner. 1997. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin. Infect. Dis. 25: 1213-1221.
2. Bermudez, L. E., and J. Goodman. 1996. Mycobacterium tuberculosis invades and replicates within type II alveolar cells. Infect. Immun. 64:1400-1406.
3. Chien, S.-C., F. A. Wong, C. L. Fowler, S. V. Callery-D'Amico, R. R. Williams, R. Nayak, and A. T. Chow. 1998. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and I-gram doses of levofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 42:885-888.
4. Falkinham, J. O., III. 1996. Epidemiology of infection by nontuberculous mycobacteria. Clin. Microbiol. Rev. 9:177-215.
5. Garcia-Rodriguez, J. A., and A. C. G. Garcia. 1993. In-vitro activities of quinolones against mycobacteria. J. Antimicrob. Chemother. 32:797-808.
6. Grassi, C. 1997. New drugs for tuberculosis. Exp. Opin. Investig. Drugs 6: 1211-1226.
7. Hart, C. A., N. J. Beeching, and B. I. Duerden. 1996. Tuberculosis into the next century. J. Med. Microbiol. 44:1-34.
8. Hoffner, S. E., L. Gezelius, and B. Olsson-Liljequist. 1997. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. J. Antimicrob. Chemother. 40:885-888.
9. Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1995. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:1341-1344.
10. Kent, P. T., and G. P. Kubica. 1985. Public health mycobacteriology: a guide for the level III laboratory. Centers for Disease Control. Atlanta, Ga.
11. Klemens, S. P., C. A. Sharpe, M. C. Rogge, and M. H. Cynamon. 1994. Activity of levofloxacin in a murine model of tuberculosis. Antimicrob. Agents Chemother. 38:1476-1479.
12. McDonough, K. A., and Y. Kress. 1995. Cytotoxicity for lung epithelial cells is a virulence-associated phenotype of Mycobacterium tuberculosis. Infect. Immun. 63:4802-4811.
13. Murata, M., E. Takahara, O. Nagata, H. Kato, I. Tamai, and A. Tsuji. 1995. Carrier-mediated tissue distribution and pharmacokinetics of HSR-903, a new quinolone, abstr. F203, p. 148. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C.
14. Okezaki, E. Personal communication.
15. Rastogi, N., K. S. Goh, A. Bryskier, and A. Devallois. 1996. In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40:1610-1616.
16. Rastogi, N., K. S. Goh, A. Bryskier, and A. Devallois. 1996. Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine. Antimicrob. Agents Chemother. 40:2483-2487.
17. Saito, H., K. Sato, H. Tomioka, and S. Dekio. 1995. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355). Tuber. Lung Dis. 76:377-380.
18. Saito, H., H. Tomioka, K. Sato, and S. Dekio. 1994. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a. Antimicrob. Agents Chemother. 38:2877-2882.
19. Sato, K., T. Akaki, and H. Tomioka. 1998. Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages. J. Antimicrob. Chemother. 41:77-83.
20. Sato, K., and H. Tomioka. 1999. Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex residing in murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells. J. Antimicrob. Chemother. 43:351-357.
21. Takahashi, Y., N. Masuda, M. Otsuki, M. Miki, and T. Nishino. 1997. In vitro activity of HSR-903, a new quinolone. Antimicrob. Agents Chemother. 41:1326-1330.
22. Tomioka, H., H. Saito, and K. Sato. 1993. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Antimicrob. Agents Chemother. 37:1259-1263.
23. Tomioka, H., K. Sato, H. Saito, and Y. Yamada. 1989. Susceptibility of Mycobacterium avium and Mycobacterium intracellulare to various antibacterial drugs. Microbiol. Immunol. 33:509-514.
24. Umemura, K., A. Mizuno, and M. Nakashima. 1996. Pharmacokinetics and safety of HSR-903 in healthy volunteers. abstr. F60, p. 110. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
25. Watanabe, A., Y. Tokue, H. Takahashi, T. Kikuchi, T. Kobayashi, K. Gomi, S. Fujiwara, and T. Nukiwa. 1999. In vitro activity of HSR-903, a new oral quinolone, against bacteria causing respiratory infections. Antimicrob. Agents Chemother. 43:1767-1768.
26. Yajuko, D. M., P. S. Nassos, and W. K. Hadley. 1987. Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome. Antimicrob. Agents Chemother. 31:1579-1584.
27. Yew, W. W., K. F. Au, J. Lee, and C. H. Chau. 1997. Levofloxacin in treatment of drug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 1:89.
28. Yoshizumi, S., H. Domon, S. Miyazaki, and K. Yamaguchi. 1998. In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. Antimicrob. Agents Chemother. 42:785-788.
29. Young, L. S. 1996. Mycobacterial infections in immunocompromised patients. Curr. Opin. Infect. Dis. 9:240-245.